Comprehensive treatment of recurrent ovarian cancer. Clinical case
Article Sidebar
Main Article Content
Abstract
This clinical case represents a medical hіstory of a 47-year-old patient S., who consulted an oncologist with complaints of abdominal enlargement and general weakness. The ovarian cancer FIGO stage IVB (metastases to the omentum, liver, spleen, and peritoneal carcinomatosis) was diagnosed. The patient underwent multiple stages of combined treatment, including surgery, adjuvant and anti-relapse chemotherapy, hormone therapy, and intraperitoneal heat therapy (HIPEC). The case demonstrates the complexity of managing recurrent ovarian cancer, the importance of a personalized approach, and monitoring side effects to ensure quality of life.
Article Details
Copyright (c) 2025 Iryna H, et al.
This work is licensed under a Creative Commons Attribution 4.0 International License.
1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49. Available from: https://doi.org/10.3322/caac.21660
2. Matei D, Brown J, Frazier L. Advances in molecular profiling and targeted therapies in ovarian cancer. Curr Oncol Rep. 2019;21(8):71.
3. Pujade-Lauraine E, Ledermann JA, Selle F, Gebski V, Penson RT, Oza AM, et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT Ov21): a double blind, randomised, placebo controlled, phase 3 trial. Lancet Oncol. 2017;18(9):1274–84. Available from: https://doi.org/10.1016/S1470-2045(17)30469-2
4. Borella F, Fucina S, Mangherini L, Cosma S, Carosso AR, Cusato J, et al. Hormone receptors and epithelial ovarian cancer: recent advances in biology and treatment options. Biomedicines. 2023;11(8):2157. Available from: https://doi.org/10.3390/biomedicines11082157
5. Kato S, McFall T, Takahashi K, Bamel K, Ikeda S, Eskander RN, et al. KRAS mutated, estrogen receptor positive low grade serous ovarian cancer: unraveling an exceptional response mystery. Oncologist. 2021;26(4):e530–e536. Available from: https://doi.org/10.1002/onco.13702
6. Zhu C, Guan X, Zhang X, Luan X, Song Z, Cheng X, et al. Targeting KRAS mutant cancers: from druggable therapy to drug resistance. Mol Cancer. 2022;21(1):159. Available from: https://doi.org/10.1186/s12943-022-01629-2
7. U.S. Food and Drug Administration… FDA grants accelerated approval to the combination of avutometinib and defactinib for KRAS mutated recurrent low grade serous ovarian cancer. FDA. May 8, 2025. Available from: FDA grants accelerated approval… en.wikipedia.org+3pharmacytimes.com+3ascopost.com+3reuters.com+15fda.gov+15ons.org+15
8. Beliak V, Bilobryvka R, Slipetsky R, Yakubets O, Volodko N. NCCN distress thermometer as a screening tool for detecting psychoemotional disorders in patients with malignant tumors of the female reproductive system. Proc Shevchenko Sci Soc Med Sci. 2024;73(1). Available from: https://doi.org/10.25040/ntsh2024.01.14